Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the breast international group 02-98 phase III trial

C. Oakman, P. A. Francis, J. Crown, E. Quinaux, M. Buyse, E. De azambuja, M. Margeli vila, M. Andersson, B. Nordenskjöld, R. Jakesz, B. Thürlimann, J. Gutiérrez, V. Harvey, L. Punzalan, P. Dell'Orto, D. Larsimont, I. Steinberg, R. D. Gelber, M. Piccart-Gebhart, G. VialeA. Di Leo

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the breast international group 02-98 phase III trial'. Together they form a unique fingerprint.

Medicine & Life Sciences